• The Scope of Things: Bridging Health Equity in Clinical Research

    Clinical Research News | Among the shifting tides around DEI, people are finding creative ways to keep the momentum going for equitable clinical trials. Ramona Burress, co-founder of Onyx Health Collective, and Cassandra O’Neal, founder of Illuminated Arc Consulting, discuss a practical look at health equity in clinical trials in the latest episode of The Scope of Things.

    May 6, 2026

  • Much Progress Needed Planning Research to Consider Sex as a Biological Variable

    Clinical Research News | In 2016, the National Institutes of Health (NIH) introduced a policy requiring grantees to consider sex as a biological variable in their experimental design, analyses, and reporting. Now a team from Northwestern University has assessed progress, highlighting significant room for improvement.

    May 5, 2026

  • Much Progress Needed Planning Research to Consider Sex as a Biological Variable

    Clinical Research News | In 2016, the National Institutes of Health (NIH) introduced a policy requiring grantees to consider sex as a biological variable in their experimental design, analyses, and reporting. Now a team from Northwestern University has assessed progress, highlighting significant room for improvement.

    May 5, 2026

  • Follow the Money: AKT1-Selective Inhibitors, Vision Restoration Treatments, Neurology and Neuropsychiatric Treatments

    Clinical Research News | Terremoto Biosciences advances lead AKT1-selective inhibitor programs through phase 1 clinical development; Ray Therapeutics provides support of late-stage clinical development and commercial readiness for the company’s lead program in retinitis pigmentosa; Tortugas advances its two lead candidates; and more.

    Apr 30, 2026

  • FDA Piloting Real-Time Review of Clinical Trial Data From AstraZeneca, Amgen

    Clinical Research News | The U.S. Food & Drug Administration is piloting real-time review of data from AstraZeneca and Amgen clinical trials, both using Paradigm Health's Study Conduct platform, and has issued a call for feedback on how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials. FDA has already received and validated signals for AstraZeneca’s trial and expects this to be the first step in implementing real-time clinical trials (RTCT).

    Apr 29, 2026

  • Discovery Life Sciences, Mindpeak Partnership, Streamlining Communications, Rare Disease Referrals

    Clinical Research News | Discovery Life Sciences and Mindpeak enter a partnership; Cenevo has launched the Labguru Customer Portal; myTomorrows and Rare Disease Research team up; and more.

    Apr 28, 2026

  • Lung Cancer Trial Trends Show Geographic Concentration

    Clinical Research News | In research presented this week at the American Association for Cancer Research (AACR) Annual Meeting, trends surfaced showing that between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities.

    Apr 23, 2026

  • Pistoia Alliance Furthers Research on Using Social Media Listening in Drug Discovery, Clinical Research

    Clinical Research News | In an expansion of its advocacy work into clinical fields, the Pistoia Alliance has launched new patient research to shape the ethical use of social media listening in drug development. The work is part of its ongoing Social Media Real-World Evidence (RWE) project.

    Apr 22, 2026

  • Veristat Discovers a Goldmine of Opportunities in China

    Clinical Research News | Following an eye-opening experience at China’s largest biotechnology and life sciences event, Veristat is positioning itself as a first mover in accommodating the regulatory needs of multiple Chinese companies eager to enter European and North American markets. The shift comes in response to government policy reforms over the past decade, with purpose-built R&D cities and science parks in more recent years acting as physical accelerators.

    Apr 16, 2026